Meeting
2021 ASCO Annual Meeting
A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
Authors
Yang Li
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Yang Li , Qianqian Duan , Yuan Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2598)
DOI
10.1200/JCO.2021.39.15_suppl.2598
Abstract #
2598
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pan-cancer analysis of P21 activated kinase (PAK) family genes as potential biomarkers for immune checkpoint therapy.
First Author: Sun Gang
Poster
2021 ASCO Annual Meeting
Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.
First Author: Jie Gao
Poster
2023 ASCO Annual Meeting
A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.
First Author: Wei Wang
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang